luminespib
Sign in to saveAlso known as NVP-AUY922, AUY922
Luminespib (INN, previously known as NVP-AUY922) is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis and licensed to Novartis. From 2011 to 2014 it was in Phase II clinical trials. Chemically it is a resorcinylic isoxazole amide
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
{{Chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 462257909 | ImageFile = Luminespib.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = 5-[2,4-Dihydroxy-5-(propan-2-yl)phenyl]-N-ethyl-4-{4-[(morpholin-4-yl)methyl]phenyl}-1,2-oxazole-3-carboxamide | OtherNames = NVP-AUY-922; AUY922; VER-52296
| Section1 =
Excerpted from Wikipedia’s “luminespib” article, available under the CC BY-SA 4.0 licence.